Year: 2017
Type: review
Abstract: Aims: PCSK9 genetic variants that have large effects on low-density lipoprotein cholesterol (LDL-C) and coronary heart disease (CHD) have prompted the development of therapeutic PCSK9-inhibition. However, there is limited evidence that PCSK9 variants are associated with ischaemic stroke (IS). Methods and results: Associations of the loss-of-function PCSK9 genetic variant (rs11591147; R46L), and five additional PCSK9 variants, with IS and IS subtypes (cardioembolic, large vessel, and small vessel) were estimated in a meta-analysis involving 10 307 IS cases and 19 326 controls of European ancestry. They were then compared with the associations of these variants with LDL-C levels (in up to 172 970 individuals) and CHD (in up to 60 801 CHD cases and 123 504 controls). The rs11591147 T allele was associated with 0.5 mmol/L lower LDL-C level (P = 9 × 10-143) and 23% lower CHD risk [odds ratio (OR): 0.77, 95% confidence interval (CI): 0.69-0.87, P = 7 × 10-6]. However, it was not associated with risk of IS (OR: 1.04, 95% CI: 0.84-1.28, P = 0.74) or IS subtypes. Information from additional PCSK9 variants also indicated consistently weaker effects on IS than on CHD. Conclusion: PCSK9 genetic variants that confer life-long lower PCSK9 and LDL-C levels appear to have significantly weaker, if any, associations with risk of IS than with risk of CHD. By contrast, similar proportional reductions in risks of IS and CHD have been observed in randomized trials of therapeutic PCSK9-inhibition. These findings have implications for our understanding of when Mendelian randomization can be relied upon to predict the effects of therapeutic interventions.
Source: European Heart Journal
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $2,535
Funders: U.S. Department of Veterans Affairs, American Heart Association, AstraZeneca, Office of Research and Development, University of Michigan, Johns Hopkins University, Wellcome Trust, Broad Institute, Corona-Stiftung, Mylan, Cancer Research UK, National Institute for Health and Care Research, British Heart Foundation, Scottish Funding Council, Stroke Association, UK-India Education and Research Initiative, University of Oxford, European Commission, Henry Smith Charity, National Stroke Foundation, Deutsche Forschungsgemeinschaft, Fondation Leducq, Bundesministerium für Bildung und Forschung, Ministero della Salute, Stiftung zur Erforschung der Vaskulären Demenz, Vincent Fairfax Family Foundation, National Institutes of Health, Centers for Disease Control and Prevention, College of Pharmacy, University of Michigan, U.S. Public Health Service, Medical Research Council, National Health and Medical Research Council, NIHR Oxford Biomedical Research Centre, National Institute on Aging, National Heart, Lung, and Blood Institute, National Human Genome Research Institute, National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke, National Center for Research Resources, NIH Clinical Center, Office of Research on Women's Health
Awards: G1007715963, G1044594144, WTCCC2 core activities., G1474772629, G2146332128, WTCCC2 core activities, A Genome-wide Association Study for Early-Onset Myocardial Infarction, G3156332283, Pharmacogenomic, genetic and trial-based studies of lipid-modifying therapies and vascular risk, Statistical Methods for Gene Environment Interactions In Lung Cancer, G337639696, Randomized Clinical Trials - Whole Genome Studies Coordinating Center, Sharing capacity across Europe in high-throughput sequencing technology to explore genetic variation in health and disease, G4700852728, A Center for GEI Association Studies, Pharmacogenomic studies in VISP: results & implications for clinical trial design, Genetic Risk to Stroke in Smokers and Nonsmokers in Two Ethnic Groups, Genetic Predictors for DNA Repair Phenotype in CMM, Mid-Atlantic Nutrition Obesity Research Center, G7093047072, GWAS of Hormone Treatment and CVD and Metabolic Outcomes in the WHI, WTCCC2 core activities., The NINDS International Stroke Genetics Consortium Study
OpenAlex ID: W2766392615
